Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
6.18
+0.52 (9.19%)
At close: Jan 27, 2026, 4:00 PM EST
5.27
-0.91 (-14.72%)
Pre-market: Jan 28, 2026, 4:57 AM EST
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,422,288
Market Cap
674.58M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | 43 | 18 | 72.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gyre Therapeutics | 579 |
| MeiraGTx Holdings | 409 |
| REGENXBIO | 353 |
| ProKidney | 204 |
| Rigel Pharmaceuticals | 164 |
| Alpha Tau Medical | 125 |
| Cullinan Therapeutics | 111 |
| Lexicon Pharmaceuticals | 103 |
ALT News
- 7 hours ago - Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 22 days ago - Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - GlobeNewsWire
- 5 weeks ago - Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
- 5 weeks ago - Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks - Benzinga
- 5 weeks ago - Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript - Seeking Alpha
- 5 weeks ago - Altimmune's drug for a type of liver disease shows benefits in mid-stage study - Reuters
- 5 weeks ago - Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial - GlobeNewsWire
- 2 months ago - Altimmune Announces CEO Transition and Succession Plan - GlobeNewsWire